Novo Nordisk wins EU panel's backing for key diabetes drug

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk came closer to winning European approval for diabetes drug Ozempic, its biggest growth prospect, when a European Medicines Agency (EMA) experts' panel issued a positive recommendation on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news